Showing 1 - 10 of 148
We investigate entry in a dynastic entrepreneurship (overlapping generations) environment created by employee spinoffs …, optimal entry of original firms and all subsequent employee spinoffs is achieved, despite the fact that the original firm can … increases the rate of spinoffs from original firms. Indeed, if employers have all the bargaining power vis-à-vis their employees …
Persistent link: https://www.econbiz.de/10010528295
This paper proposes a novel approach to evaluate location decisions for public facilities. The approach addresses, not … only the standard distance-minimizing problem, but also the endogenous location decisions of individuals. To do so, I …, commutes to work and public facilities, as well as public facility characteristics. The latter includes a facility’s location …
Persistent link: https://www.econbiz.de/10012437902
entry by generic producers. Reference pricing shifts demand towards generics but also induces the branded producer to become … more agressive, which triggers price competition and potentially deters entry by generic producers. To investigate the … expenditures. Thus, we find no evidence for a countervailing entry deterring effect of reference pricing. …
Persistent link: https://www.econbiz.de/10013285854
There were no innovations in chemotherapy for myeloma patients during the period 1977-1997, but there have been several important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma patients using both time-series U.S. data and...
Persistent link: https://www.econbiz.de/10010223067
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
We study the impact of product margins on pharmacies' incentive to promote generics instead of brand-names. First, we construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to purchase a generic version instead. We show that pharmacies' substitution...
Persistent link: https://www.econbiz.de/10009691207
This paper assesses sources of productivity spillovers in China's electric and electronic manufacturing industry using a rich panel data-set of 25,360 firms observed over the period 2004-2007. This industry is characterized by its important reliance on technology. In particular, the paper...
Persistent link: https://www.econbiz.de/10010356360
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...
Persistent link: https://www.econbiz.de/10008749029
Using an extensive longitudinal dataset extracted from the Norwegian Prescription Database (NorPD) containing all prescriptions written in the period January 2004 to June 2007, we selected two particular drugs (chemical substances) used against cholesterol. The two brand-name products on the...
Persistent link: https://www.econbiz.de/10008697144
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10009571756